Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs

Experimental and Toxicologic Pathology

Volumn 51, Issue 6, 1999, Pages 507-516

  Classen, W ^a   Altmann, B ^a   Gretener, P ^a   Souppart, C ^a   Skelton Stroud, P ^a   Krinke, G ^a,b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Text Mining Services   (Switzerland)

Author keywords

Antimalarial; Artemether; Artemisinin; Neurotoxicity; Qinghaosu; Toxicity

Indexed keywords

ARTEMETHER; DIHYDROARTEMISININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; MALE; NEUROPATHY; NEUROTOXICITY; NISSL SUBSTANCE; NONHUMAN; QT INTERVAL;

ANIMALIA; ARTEMISIA ANNUA; CANIS FAMILIARIS;

EID: 0033391112     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0940-2993(99)80128-6     Document Type: Article

References (14)

1. BREWER TG, GRATE SJ, PEGGINS JO, et al.: Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994a; 51: 251-259.
2. BREWER TG, PEGGINS JO, GRATE SJ, et al.: Neurotoxicity in animals due to arteether and artemether. Transactions of the Royal Society of Tropical Medicine and Hygiene 1994b; 88 Suppl 1: 33-36.
3. CEBALLOS-PICOT I: The Role of Oxidative Stress in Neuronal Death. Landes Bioscience, Austin, Texas 1997; 203 pp.
4. GENOVESE RF, PETRAS JM, BREWER TG: Arteether neurotoxicity in the absence of deficits in behavioral performance in rats. Annals of Tropical Medicine and Parasitology 1995, 89: 447-449.
5. KAMCHONWONGPAISAN S, MCKEEVER P, HOSSLER P, et al.: Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am J Trop Med Hyg 1997; 56: 7-12.
6. KARBWANG J, NA BANGCHANG K, CONGPUONG K, et al.: Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur J clin Pharmacol 1997; 52: 307-310.
7. KRINKE G, NAYLOR DC, SKORPIL V: Pyridoxine megavitaminosis: an analysis of the early changes induced with massive doses of vitamin B6 in rat primary sensory neurons. Journal of Neuropathology and Experimental Neurology 1985; 44: 117-129.
8. KRINKE GJ, FITZGERALD RE: The pattern of pyridoxine-induced lesions: difference between the high and the low toxic level. Toxicology 1988; 49: 171-178.
9. NA BANGCHANG K, KARBWANG J, THOMAS CG, et al.: Pharmacokinetics of artemether after oral administration to healthy Thai males and patients with acute, uncomplicated falciparum malaria. Br J clin Pharmacol 1994; 37: 249-253.
10. PETRAS JM, KYLE DE, NGAMPOCHJANA M, et al.: Arteether induced brainstem injury in macaca mulatta. Am J Trop Med Hyg 1994; 51: 100.
11. SANDRENAN N, SIOUFI A, GODBILLON J, et al.: Determination of artemether and ist metabolite, dihydroartemisinin, in plasma by high-performance liquid chromatography and electrochemical detection in the reductive mode. J Chromatogr B 1997; 691: 145.
12. SUMMERS BA, CUMMINGS JF, DELAHUNTA A: Veterinary Neuropathology. Mosby-Year Book Inc. St. Louis, Baltimore, Berlin etc. 1995; p. 527.
13. TEJA-ISAVADHARM P, NOSTEN F, KYLE DE, et al.: Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. Br J clin Pharmacol 1996; 42: 599-604.
14. ZHOU Z, HUANG Y, XIE G, et al.: HPLC with polarographic detection of artemisinin and its derivatives and application of the method to the pharmacokinetic study of artemether. J Liquid Chromatogr 1988; 11: 1117-1137.